Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer
Of the thousands of genes and substrates identified in KRAS-mutant signaling networks in pancreatic ductal adenocarcinoma (PDAC), more than 200 are transcription factors, implying extensive and complex transcriptional regulation. However, we observed that genetic suppression of the transcription factor MYC alone was sufficient to phenocopy the effect of KRAS suppression in signaling, growth, and metabolic processes in PDAC cells. We determined the gene transcription changes caused by acute suppression of MYC function in <i>KRAS</i>-mutant PDAC cell lines and performed dependency map and pathway analyses on the affected gene sets. The expression of 1685 genes was increased upon suppression of MYC, and this gene set may comprise the bulk of the MYC-regulated genes essential for PDAC growth. In contrast, the 1325 genes whose expression was inhibited may comprise a compensatory response to oncogenic stress, mediated in part by the GTPase RHO. MYC-dependent transcriptional activity was largely ERK dependent, and almost one-third of ERK-regulated genes were also regulated by MYC in PDAC cells. Furthermore, chemical proteomic profiling revealed MYC-regulated protein kinases that can be targeted therapeutically. Together, these data provide a molecular portrait of MYC-dependent signaling that encompasses potentially exploitable mechanisms for treating PDAC.
Authors
- Jennifer E. Klomp (ORCID: https://orcid.org/0000-0003-1781-648X)
- A. Cole Edwards (ORCID: https://orcid.org/0000-0001-9220-9642)
- Clint A. Stalnecker (ORCID: https://orcid.org/0000-0002-0570-4416)
- Adrienne D. Cox (ORCID: https://orcid.org/0000-0002-4901-2454)
- Kristina Drizyte‐Miller (ORCID: https://orcid.org/0000-0001-7049-2934)
- Nhan L. Tran (ORCID: https://orcid.org/0000-0003-0908-9964)
- Richard G. Hodge (ORCID: https://orcid.org/0000-0002-1920-1385)
- Natalie K. Barker (ORCID: https://orcid.org/0000-0001-9248-2710)
- Andrew M. Waters (ORCID: https://orcid.org/0000-0002-6058-5878)
- Kayla R. Snare
- Ryan D. Mouery (ORCID: https://orcid.org/0000-0002-1866-1742)
- Priya S. Hibshman
- Laura E. Herring (ORCID: https://orcid.org/0000-0003-4496-7312)
- Jeffrey A. Klomp (ORCID: https://orcid.org/0000-0002-5243-6987)
- Channing J. Der (ORCID: https://orcid.org/0000-0002-7751-2747)
- Naim U. Rashid (ORCID: https://orcid.org/0000-0002-7274-8259)
- Mariaelena Pierobon (ORCID: https://orcid.org/0000-0003-2084-1029)
- Kirsten L. Bryant (ORCID: https://orcid.org/0000-0003-4026-0942)
- Brandon L. Mouery (ORCID: https://orcid.org/0000-0002-8900-3413)
- J. Nathaniel Diehl (ORCID: https://orcid.org/0000-0002-7309-0903)
- Lee M. Graves (ORCID: https://orcid.org/0000-0002-4736-9855)
- Sen Peng
- Emanuel F. Petricoin (ORCID: https://orcid.org/0000-0001-8787-5990)
- Lily M. Pita
Institutions
- University of North Carolina at Chapel Hill (US)
- George Mason University (US)
- Illumina (United States) (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Science Signaling
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1126/scisignal.adu7145
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00